Published November 2019 | Version v1
Journal article

Development of a 18F-labeled PET radioligand for imaging 5-HT1B receptors: [18F]AZ10419096

  • 1. Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892-1003 (United States)
  • 2. Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-17176 Stockholm (Sweden)
  • 3. PET Science Centre, Precision Medicine and Genomics, R&D, AstraZeneca, SE-17176 Stockholm (Sweden)
  • 4. Isotope Chemistry, Early Chemical Development, Pharmaceutical Sciences R&D, AstraZeneca, SE-43250 Göteborg (Sweden)

Description

In the last decade PET has been useful in studying and understanding the 5-HT1B receptor. [11C]AZ10419369 and [11C]P943 have been applied as radioligands in these studies. Both use carbon-11 (t1/2 = 20.4 min) as radionuclide, which limits the application to PET centres that have an on-site cyclotron and radiochemistry facilities. In this paper we report the synthesis and initial evaluation of the first fluorine-18 PET radioligand to image 5-HT1B receptors in brain, [18F]AZ10419096.

Additional details

Identifiers

DOI
10.1016/j.nucmedbio.2019.10.003;
PII
S0969805119301726;

Publishing Information

Journal Title
Nuclear Medicine and Biology
Journal Volume
78
Journal Page Range
p. 11-16
ISSN
0969-8051
CODEN
NMBIEO

Optional Information

Copyright
Copyright (c) 2019 Elsevier Inc. All rights reserved.